💊Pharmacology for Nurses Unit 33 – Renal and Urinary Systems Overview

Key Concepts

• Understand the basic anatomy and physiology of the renal and urinary systems including the kidneys, ureters, bladder, and urethra
• Differentiate between the functions of the renal cortex and renal medulla in filtering blood and concentrating urine
• Explain the role of nephrons as the functional units of the kidney responsible for filtering blood, reabsorbing nutrients, and excreting waste
• Describe the process of urine formation involving glomerular filtration, tubular reabsorption, and tubular secretion
• Recognize common renal disorders such as acute kidney injury, chronic kidney disease, nephrotic syndrome, and urinary tract infections
• Identify pharmacological interventions used to treat renal disorders and manage symptoms
• Understand the mechanisms of action, indications, and contraindications of various drug classes used in renal and urinary disorders
• Consider nursing implications when administering medications for renal and urinary disorders, including patient assessment, monitoring, and education

Anatomy and Physiology Basics

• The renal system consists of two kidneys located in the retroperitoneal space, responsible for filtering blood and maintaining fluid and electrolyte balance
  • Each kidney is composed of an outer renal cortex and an inner renal medulla
  • The renal cortex contains glomeruli, which are clusters of capillaries involved in the initial filtration of blood
  • The renal medulla consists of renal pyramids and collecting ducts, which concentrate urine and regulate its composition
• Nephrons are the functional units of the kidney, each consisting of a glomerulus, proximal convoluted tubule, loop of Henle, distal convoluted tubule, and collecting duct
  • Glomerular filtration occurs in the glomerulus, where blood is filtered under pressure, allowing small molecules and waste products to pass into the nephron tubule
  • Tubular reabsorption involves the selective reabsorption of essential nutrients, electrolytes, and water from the tubular fluid back into the bloodstream
  • Tubular secretion is the process by which certain substances (hydrogen ions, potassium, and drugs) are actively secreted from the peritubular capillaries into the tubular fluid
• The ureters are muscular tubes that transport urine from the kidneys to the bladder for storage
• The bladder is a hollow, muscular organ that stores urine until it is expelled from the body through the urethra during micturition (urination)

Common Renal Disorders

• Acute kidney injury (AKI) is a sudden decline in renal function, often caused by decreased renal perfusion, nephrotoxic agents, or urinary tract obstruction
  • Symptoms of AKI include decreased urine output (oliguria), fluid retention, and electrolyte imbalances
• Chronic kidney disease (CKD) is a progressive loss of renal function over time, characterized by a decreased glomerular filtration rate (GFR) and the presence of kidney damage markers
  • CKD can be caused by diabetes, hypertension, glomerulonephritis, and polycystic kidney disease
  • Patients with CKD may experience anemia, bone mineral disorders, and cardiovascular complications
• Nephrotic syndrome is a group of symptoms resulting from increased glomerular permeability, leading to proteinuria, hypoalbuminemia, edema, and hyperlipidemia
• Urinary tract infections (UTIs) are common bacterial infections affecting the bladder (cystitis), urethra (urethritis), or kidneys (pyelonephritis)
  • Symptoms of UTIs include dysuria, frequency, urgency, and suprapubic pain
  • Risk factors for UTIs include female anatomy, sexual activity, and urinary tract abnormalities (urinary stasis, catheterization)

Pharmacological Interventions

• Diuretics are used to promote urine production and reduce fluid overload in conditions such as heart failure, hypertension, and edema
  • Loop diuretics (furosemide) inhibit sodium and chloride reabsorption in the loop of Henle, leading to increased urine output
  • Thiazide diuretics (hydrochlorothiazide) act on the distal convoluted tubule to promote natriuresis and diuresis
• Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are used to manage hypertension and slow the progression of CKD
  • ACE inhibitors (lisinopril) block the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion
  • ARBs (losartan) block the binding of angiotensin II to its receptor, producing similar effects to ACE inhibitors
• Phosphate binders (calcium acetate, sevelamer) are used to control hyperphosphatemia in patients with CKD by binding to dietary phosphate in the gastrointestinal tract
• Erythropoiesis-stimulating agents (ESAs) such as epoetin alfa and darbepoetin alfa are used to treat anemia associated with CKD by stimulating red blood cell production
• Antibiotics are used to treat UTIs, with the choice of agent depending on the location and severity of the infection, as well as local resistance patterns
  • Nitrofurantoin and trimethoprim-sulfamethoxazole are commonly used for uncomplicated cystitis
  • Fluoroquinolones (ciprofloxacin) and extended-spectrum cephalosporins may be used for more severe infections or pyelonephritis

Drug Classes and Mechanisms

• Diuretics act on different segments of the nephron to inhibit sodium and water reabsorption, leading to increased urine output
  • Loop diuretics (furosemide) inhibit the Na+-K+-2Cl- cotransporter in the thick ascending limb of the loop of Henle
  • Thiazide diuretics (hydrochlorothiazide) inhibit the Na+-Cl- cotransporter in the distal convoluted tubule
  • Potassium-sparing diuretics (spironolactone) block the action of aldosterone in the collecting duct, reducing potassium excretion
• ACE inhibitors (lisinopril) block the conversion of angiotensin I to angiotensin II by inhibiting the angiotensin-converting enzyme
  • This reduces vasoconstriction, aldosterone secretion, and renal sodium and water retention
• ARBs (losartan) selectively block the binding of angiotensin II to the AT1 receptor, producing similar effects to ACE inhibitors
• Phosphate binders work by different mechanisms to reduce the absorption of dietary phosphate in the gastrointestinal tract
  • Calcium-based binders (calcium acetate) form insoluble complexes with phosphate, preventing its absorption
  • Sevelamer is a non-calcium, non-aluminum binder that binds phosphate through ion exchange
• ESAs (epoetin alfa, darbepoetin alfa) stimulate erythropoiesis by binding to and activating the erythropoietin receptor on red blood cell precursors in the bone marrow
• Antibiotics used for UTIs have various mechanisms of action depending on the class
  • Nitrofurantoin inhibits bacterial DNA, RNA, and cell wall synthesis
  • Trimethoprim-sulfamethoxazole inhibits bacterial folate synthesis by blocking dihydrofolate reductase and dihydropteroate synthase
  • Fluoroquinolones (ciprofloxacin) inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication

Nursing Considerations

• Assess renal function through laboratory tests such as serum creatinine, blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR) before initiating therapy and periodically during treatment
• Monitor fluid balance, including intake and output, daily weights, and signs of fluid overload (edema, dyspnea) or dehydration (hypotension, tachycardia)
• Assess electrolyte levels, particularly potassium, sodium, and magnesium, as renal disorders and medications can cause imbalances
  • Monitor for signs of hyperkalemia (muscle weakness, ECG changes) when using ACE inhibitors, ARBs, or potassium-sparing diuretics
• Administer medications at the prescribed dose and frequency, adjusting based on renal function and therapeutic response
• Encourage adherence to dietary restrictions, such as limiting sodium, potassium, phosphate, and protein intake as appropriate for the patient's condition
• Provide patient education on the proper use of medications, potential side effects, and the importance of regular follow-up with healthcare providers
• Collaborate with the interprofessional team, including nephrologists, dietitians, and social workers, to provide comprehensive care for patients with renal disorders

Side Effects and Interactions

• Diuretics can cause electrolyte imbalances, particularly hypokalemia, hyponatremia, and hypomagnesemia
  • Loop and thiazide diuretics can also cause volume depletion, leading to hypotension and renal dysfunction
  • Potassium-sparing diuretics may cause hyperkalemia, especially when used in combination with ACE inhibitors, ARBs, or NSAIDs
• ACE inhibitors and ARBs can cause hypotension, hyperkalemia, and a decline in renal function, particularly in patients with pre-existing renal impairment or volume depletion
  • These agents should be used with caution in patients with bilateral renal artery stenosis or a solitary kidney
• Phosphate binders can cause gastrointestinal side effects, such as nausea, vomiting, and constipation
  • Calcium-based binders may contribute to hypercalcemia and vascular calcification in patients with CKD
• ESAs can increase the risk of thrombotic events, hypertension, and pure red cell aplasia (a rare complication)
  • ESAs should be used judiciously and at the lowest effective dose to maintain hemoglobin levels within the target range
• Antibiotics used for UTIs can cause gastrointestinal side effects (nausea, diarrhea) and allergic reactions
  • Nitrofurantoin can cause pulmonary toxicity and should be avoided in patients with impaired renal function
  • Fluoroquinolones can cause tendinopathy and QT prolongation, and should be used with caution in elderly patients or those with pre-existing risk factors

Patient Education and Monitoring

• Educate patients on the importance of adhering to their prescribed medication regimen and attending regular follow-up appointments with their healthcare providers
• Instruct patients to report any signs or symptoms of worsening renal function, such as decreased urine output, swelling, or shortness of breath
• Teach patients how to properly measure and record their fluid intake and output, and to report significant changes to their healthcare team
• Emphasize the importance of maintaining a healthy lifestyle, including regular exercise, smoking cessation, and stress management, to help manage renal disorders and prevent complications
• Educate patients on the signs and symptoms of UTIs and the importance of seeking prompt medical attention for timely diagnosis and treatment
  • Encourage patients to practice good hygiene habits, such as wiping from front to back and avoiding prolonged use of irritating products (douches, spermicides)
• Provide patients with information on dietary modifications specific to their renal disorder, such as limiting sodium, potassium, phosphate, or protein intake as recommended by their healthcare team
  • Refer patients to a registered dietitian for personalized nutrition counseling and meal planning
• Instruct patients on the proper use and storage of their medications, as well as potential side effects and interactions to be aware of
  • Advise patients to inform all healthcare providers, including dentists and pharmacists, about their renal disorder and medication regimen to avoid potential drug interactions or complications
• Encourage patients to engage in self-management activities, such as monitoring their blood pressure, blood glucose, and weight, and keeping a record of their results to share with their healthcare team
• Emphasize the importance of staying up-to-date with vaccinations, particularly influenza and pneumococcal vaccines, to reduce the risk of infections that can compromise renal function